Growing number of overweight individuals are not happy with the performance of over-the-counter diet pills alli. As a result, alli is not getting substantial positive response and it’s disappearing gradually from store shelves across different region. But for dieters, there is good news, European regulators’ decision to allow diet drug Acomplia (rimonabant) to enter the market can only be seen as a glimmer of hope.

Rimonabant, the first weight-loss drug which works by blocking CB-1 receptors in the brain will be on sale in the European Union. But in deciding to continue to permit Acomplia to be sold throughout the European Union, the European Medicines Agency (EMEA) virtually insured that enough people will take the diet drug over the next two years to provide the FDA with all the data it will need for approval.

The European agency said the benefits of rimonabant overshadow its risks but the drug is contraindicated in patients with major depression or those taking antidepressants. And the medication should be discontinued if the patient develops depression, the EMEA recommends.

In a clinical trial, a quarter of participants who took rimonabant for a year lost approximately 10 percent of their body weight, and about half lost 5 percent or more of their body weight.

In contrast, GlaxoSmithKline, of course, was upfront about telling purchasers that with a reduced-calorie, low-fat diet and exercise program can help dieters lose 50 percent more weight than they would otherwise.